A new treatment has potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a PARP inhibitor has been shown to significantly reduce the risk of breast cancer returning in high-risk patients following completion of standard chemotherapy, surgery and radiation therapy.
from Latest Science News -- ScienceDaily https://ift.tt/2Rp5PvL
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment